Dinsmore Wallace
Royal Victoria Hospital, Grosvenor Road, Belfast BT12 6BA, UK.
Int J STD AIDS. 2004 Apr;15(4):215-21. doi: 10.1258/095646204773557721.
Erectile dysfunction (ED) is an inability to attain or maintain an erection sufficient for satisfactory sexual intercourse. It is an undertreated and underdiagnosed condition that can be due to vasculogenic, neurogenic, hormonal and psychogenic factors. Effective treatment of ED should restore quality of life and allow patients to return to the sex life they had before. Current therapeutic options include non-pharmacological treatments, locally administered drugs and oral therapies. The oral phosphodiesterase-5 (PDE5) inhibitors are considered first-line treatments of ED and have revolutionized ED management in the last five years. Three PDE5 inhibitors are currently available, sildenafil, vardenafil and tadalafil. They are all effective with similar efficacy and good safety profiles. However, tadalafil has the added benefit of a broad window opportunity offering patients more freedom to choose when to initiate sexual activity.
勃起功能障碍（ED）是指无法获得或维持足以进行满意性交的勃起状态。它是一种治疗不足且诊断不足的病症，可能由血管性、神经性、激素性和心理性因素引起。ED的有效治疗应恢复生活质量，并使患者能够恢复到以前的性生活状态。目前的治疗选择包括非药物治疗、局部给药和口服疗法。口服磷酸二酯酶5（PDE5）抑制剂被认为是ED的一线治疗药物，并且在过去五年中彻底改变了ED的治疗方式。目前有三种PDE5抑制剂，即西地那非、伐地那非和他达拉非。它们都有效，疗效相似且安全性良好。然而，他达拉非还有一个额外的好处，即有更宽的用药时间窗，这为患者提供了更多选择何时开始性活动的自由。
